Steryl glucosides as a novel chemosensitizer: Enhancing doxorubicin response in estrogen receptor-positive breast cancer

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research investigates the role of steryl glucosides as chemosensitizers to enhance doxorubicin efficacy in estrogen receptor-positive breast cancer.
MCF-7 breast cancer model tested with SG and doxorubicin combinations to assess cytotoxicity and cell viability.
Dose-response analysis and Bliss independence modeling conducted to evaluate combined activity of SG and doxorubicin.
Xenograft model used to monitor tumor growth in ovariectomized, estradiol-supplemented conditions.
SG co-treatment increased doxorubicin cytotoxicity, enhancing tumor necrosis and signaling for DNA damage.
Lowest mean tumor growth trajectory observed in the SG-doxorubicin group compared to doxorubicin alone, with reduced tumor burden and weight.
MCF-7 model showed significant results, though T47D data indicated variability in response.

We only have this paper's title and publication details.

Shows increased doxorubicin response in MCF-7 breast cancer models, suggesting a potential new treatment approach.

No takes yet. Share an insight, caveat, or question.

Cavalcanti-Neto et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Share